Treatment of large-vessel vasculitis (LVV) remains challenging. Patients usually respond to glucocorticoid (GC) therapy, but often relapse on tapering of the GC dose or after GC withdrawal. In addition, GCs are fraught with numerous adverse events. The aim of this study was to assess the efficacy and safety of the anti-IL-6 receptor (IL-6R) antibody tocilizumab (TCZ) in patients with LVV.

Tocilizumab: a novel therapy for patients with large-vessel vasculitis / Salvarani, Carlo; Magnani, Luca; Catanoso, Mariagrazia; Pipitone, Nicolò; Versari, Annibale; Dardani, Lucia; Pulsatelli, Lia; Meliconi, Riccardo; Boiardi, Luigi. - In: RHEUMATOLOGY. - ISSN 1462-0332. - 51:(2012), pp. 151-156. [10.1093/rheumatology/ker296]

Tocilizumab: a novel therapy for patients with large-vessel vasculitis

SALVARANI, CARLO;
2012

Abstract

Treatment of large-vessel vasculitis (LVV) remains challenging. Patients usually respond to glucocorticoid (GC) therapy, but often relapse on tapering of the GC dose or after GC withdrawal. In addition, GCs are fraught with numerous adverse events. The aim of this study was to assess the efficacy and safety of the anti-IL-6 receptor (IL-6R) antibody tocilizumab (TCZ) in patients with LVV.
2012
51
151
156
Tocilizumab: a novel therapy for patients with large-vessel vasculitis / Salvarani, Carlo; Magnani, Luca; Catanoso, Mariagrazia; Pipitone, Nicolò; Versari, Annibale; Dardani, Lucia; Pulsatelli, Lia; Meliconi, Riccardo; Boiardi, Luigi. - In: RHEUMATOLOGY. - ISSN 1462-0332. - 51:(2012), pp. 151-156. [10.1093/rheumatology/ker296]
Salvarani, Carlo; Magnani, Luca; Catanoso, Mariagrazia; Pipitone, Nicolò; Versari, Annibale; Dardani, Lucia; Pulsatelli, Lia; Meliconi, Riccardo; Boiardi, Luigi
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1078905
Citazioni
  • ???jsp.display-item.citation.pmc??? 37
  • Scopus 197
  • ???jsp.display-item.citation.isi??? 176
social impact